Thursday, November 12, 2026

Nvidia Buys Groq as US Tech Giants Lock Up AI's Global Silicon Supply Chain

Nvidia acquired LPU chip startup Groq and launched its own Vera CPUs as Broadcom finalizes custom processor deals with Alphabet and OpenAI simultaneously. The consolidation concentrates AI compute control in a handful of US firms with dedicated TSMC manufacturing capacity in Taiwan. Nations and companies outside this circle face a widening infrastructure gap with direct implications for AI sovereignty.

LM Salvado
LM Salvado

May 25, 2026

Nvidia Buys Groq as US Tech Giants Lock Up AI's Global Silicon Supply Chain
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Nvidia acquired Groq, the LPU inference chip startup, and launched its own Vera CPUs this week — completing a vertical integration play that extends well beyond American borders.1

Broadcom is simultaneously building custom AI processors for Alphabet and OpenAI, with Arm joining the OpenAI collaboration.1 Three of the world's most powerful AI operators are now co-designing the silicon that runs their models.

The consolidation concentrates AI compute authority in a small cluster of US firms with dedicated manufacturing through TSMC in Taiwan. Alphabet's TPU program, developed with Broadcom over years, is the template. What has changed is scale and simultaneity: multiple hyperscalers are locking in custom silicon relationships at the same moment.

For AI programs outside this circle — European sovereign AI initiatives, Gulf-state cloud buildouts, Indian infrastructure ambitions — the strategic gap is widening. Custom chips tuned to specific model architectures deliver better performance-per-watt than commodity GPUs. At billions of inference queries daily, that efficiency advantage compounds into significant cost separation.

Tiger Global has increased stakes in Nvidia, Broadcom, and TSMC concurrently.1 The investment pattern signals where infrastructure value accrues: not in GPU purchasing, but in custom silicon partnerships and dedicated manufacturing capacity.

Taiwan's position is central and exposed. TSMC manufactures the chips undergirding this consolidation. Geopolitical risk around the Taiwan Strait is therefore also AI infrastructure risk — a calculation European and Asian governments are actively pricing into national technology strategies.

China's push for chip independence, accelerated by US export controls, represents the only parallel vertical integration effort at comparable ambition. Chinese fabs remain multiple generations behind TSMC in leading-edge capacity, limiting near-term competitive parity.

Nvidia has an estimated 18-24 month window before custom silicon deployments create structural pressure on its commodity GPU business.1 The Groq acquisition and Vera CPU launch are direct responses to that clock.

The race to own AI's silicon stack is no longer a US domestic story. It is the central infrastructure competition shaping AI capacity worldwide.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com